Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Protocol for the Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease

Next Previous
Trial Profile

A Protocol for the Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cyclophosphamide (Primary) ; Dactinomycin (Primary) ; Filgrastim (Primary) ; Irinotecan (Primary) ; Temozolomide (Primary) ; Vincristine (Primary) ; Vinorelbine (Primary) ; Cyclophosphamide; Mesna
  • Indications Rhabdomyosarcoma
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 18 May 2025 Phase has been changed from phase I\II to II.
  • 18 May 2025 Planned number of patients changed from 100 to 135.
  • 23 Jan 2024 Planned initiation date changed from 1 Nov 2023 to 1 Feb 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top